US2007298053A1PendingUtilityA1

Cattle reproductive disease vaccines

62
Assignee: PFIZERPriority: Aug 26, 2002Filed: Aug 30, 2007Published: Dec 27, 2007
Est. expiryAug 26, 2022(expired)· nominal 20-yr term from priority
Inventors:Paul Joseph Dominowski
A61P 31/20A61P 37/04A61P 39/00A61P 31/12A61P 31/04A61P 37/02A61P 31/22A61P 31/00A61P 31/14A61P 15/06A61P 11/00A61P 15/00A61K 2039/5254A61K 39/0225C12N 2770/28022C12N 2720/10022C12N 2710/16722A61K 39/295C07K 14/005A61K 39/39C12N 2760/18522C12N 2770/24322A61K 2039/5252C12N 2760/18622A61K 39/00A61K 39/155A61K 39/265A61K 39/12
62
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to combination vaccines and methods for treating or preventing diseases or disorders in an animal caused by infection by Bovine Viral Diarrhea Virus (BVDV) Types 1 and 2, Bovine Herpes Virus Type-1 (BHV-1), Bovine Respiratory Syncytial Virus (BRSV), Parainfluenza Virus (PI 3 ), Campylobacter fetus, Leptospira canicola, Leptospira grippotyphosa, Leptospira hardj - prajitno, Leptospira icterohaemmorrhagiae, Leptospira hardjo - bovis and Leptospira pomona by administering to the animal an effective amount of a combination vaccine. The combination vaccine can be a whole or partial cell inactivated or modified live preparation.

Claims

exact text as granted — not AI-modified
1 .- 83 . (canceled)  
   
   
       84 . A vaccine composition comprising a Bovine Viral Diarrhea Virus (BVDV) and a veterinary-acceptable carrier.  
   
   
       85 . The vaccine composition according to  claim 84 , wherein said BVDV is a modified live vaccine.  
   
   
       86 . The vaccine composition according to  claim 84 , wherein said BVDV is inactivated.  
   
   
       87 . The vaccine composition according to  claim 85 , wherein said BVDV is Bovine Viral Diarrhea Virus Type-1 (BVDV-1) or Bovine Viral Diarrhea Virus Type-2 (BVDV-2).  
   
   
       88 . The vaccine composition according to  claim 86 , wherein said BVDV is Bovine Viral Diarrhea Virus Type-1 (BVDV-1) or Bovine Viral Diarrhea Virus Type-2 (BVDV-2).  
   
   
       89 . The vaccine composition according to  claim 87 , wherein said BVDV-1 and BVDV-2 are cytopathic.  
   
   
       90 . The vaccine composition according to  claim 87 , wherein said BVDV-1 and BVDV-2 are noncytopathic.  
   
   
       91 . The vaccine composition according to  claim 84 , further comprising an adjuvant.  
   
   
       92 . An immunogenic composition comprising a Bovine Viral Diarrhea Virus (BVDV) and a veterinary-acceptable carrier.  
   
   
       93 . The immunogenic composition according to  claim 92 , wherein said BVDV is a modified live vaccine.  
   
   
       94 . The immunogenic composition according to  claim 92 , wherein said BVDV is inactivated.  
   
   
       95 . The immunogenic composition according to  claim 93 , wherein said BVDV is Bovine Viral Diarrhea Virus Type-1 (BVDV-1) or Bovine Viral Diarrhea Virus Type-2 (BVDV-2).  
   
   
       96 . The immunogenic composition according to  claim 94 , wherein said BVDV is Bovine Viral Diarrhea Virus Type-1 (BVDV-1) or Bovine Viral Diarrhea Virus Type-2 (BVDV-2).  
   
   
       97 . The immunogenic composition according to  claim 95 , wherein said BVDV-1 and BVDV-2 are cytopathic.  
   
   
       98 . The immunogenic composition according to  claim 95 , wherein said BVDV-1 and BVDV-2 are noncytopathic.  
   
   
       99 . The immunogenic composition according to  claim 92 , further comprising an adjuvant.  
   
   
       100 . A method of preventing fetal infection in an animal subject, comprising administering to said animal an effective amount of the vaccine composition of  claim 84 .  
   
   
       101 . The method according to  claim 100 , wherein said fetal infection is persistent fetal infection.  
   
   
       102 . The method of  claim 100 , wherein said animal is a cow, a calf, a heifer, a steer or a bull.  
   
   
       103 . The method of  claim 102 , wherein said animal is a lactating cow.  
   
   
       104 . The method of  claim 102 , wherein said animal is a pregnant cow.  
   
   
       105 . The method of  claim 102 , wherein said animal is a prebreeding cow or heifer.  
   
   
       106 . The method of  claim 100 , wherein the amount of said vaccine administered is from about 0.5 to about 5.0 ml per dose.  
   
   
       107 . The method of  claim 106 , wherein the amount of said vaccine administered is about 5 ml per dose.  
   
   
       108 . The method of  claim 106 , wherein the amount of said vaccine administered is about 2 ml per dose.

Join the waitlist — get patent alerts

Track US2007298053A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.